Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7687627 | 0.83 | HTT (0.39) | HTTSMN1; SMN2KMT2AMAOBTSHR | |
| SCHEMBL507033 | 0.81 | MAOB (0.50) | HTTSMN1; SMN2KMT2AMAOBTSHR | |
| SCHEMBL5384421 | 0.81 | HTT (0.50) | HTTSMN1; SMN2KMT2ATSHRTDP1 | |
| SCHEMBL6944585 | 0.81 | HTT (0.47) | HTTSMN1; SMN2KMT2ATSHRTDP1 | |
| SCHEMBL1710061 | 0.81 | KMT2A (0.51) | HTTSMN1; SMN2KMT2ATSHRMAPT | |
| SCHEMBL7769868 | 0.81 | HTT (0.47) | HTTSMN1; SMN2KMT2AMAOBTSHR | |
| SCHEMBL7684463 | 0.80 | CFTR (0.47) | HTTSMN1; SMN2KMT2ATSHRMAPT | |
| SCHEMBL9682 | 0.79 | MAPT (0.63) | SMN1; SMN2KMT2AMAOBTSHRTDP1 | |
| SCHEMBL28749827 | 0.79 | HTT (0.43) | HTTSMN1; SMN2KMT2ATSHRMAPT | |
| SCHEMBL29706051 | 0.79 | HTT (0.43) | HTTSMN1; SMN2KMT2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-0866793-B1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | CHIRON CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0866793-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5814324-A | OIL IN WATER EMULSION COMPRISING ANTIFUNGAL TRIAZOLE COMPOUND DISPERSED IN WATER WITH FATTY ACID TRIGLYCERIDE, LECITHIN EMULSIFIER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-29 | — | — | US | disclosed |
| US-5792780-A | FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0657449-B1 | Azole compounds, their production and use as antifungal agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997001562-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0746318-A1 | INJECTABLE EMULSIONS CONTAINING ANTIFUNGAL TRIAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1996-12-11 | — | — | EP | disclosed |
| US-5545652-A | Triazole and imidazole compounds and their use as antifungal therapeutic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-13 | — | — | US | disclosed |
| WO-1995022973-A1 | INJECTABLE EMULSIONS CONTAINING ANTIFUNGAL TRIAZOLE DERIVATIVES | TAKEDA CHEMICALS INDUSTRIES, LTD. (JP) | 1995-08-31 | — | — | WO | disclosed |
| EP-0659751-A1 | Optically active azole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0657449-A1 | Azole compounds, their production and use as antifungal agents | Takeda Chemical Industries, Ltd. (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | HTT 3105/4885SMN1; SMN2 3501/4885KMT2A 603/4885 |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | NAT1, ERG28, DPM1 | HTT 4756/4885SMN1; SMN2 3704/4885KMT2A 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.